- Home
- BBIO vs MGM Comparison
BBIO vs MGM Comparison
Compare BBIO & MGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | MGM |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | 62000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.2B |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | BBIO | MGM |
|---|---|---|
| Price | $67.48 | $47.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 25 | 15 |
| Target Price | ★ $86.33 | $43.04 |
| AVG Volume (30 Days) | 2.8M | ★ 5.9M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.48 |
| Revenue | $502,076,000.00 | ★ $9,809,663,000.00 |
| Revenue This Year | $89.45 | $1.67 |
| Revenue Next Year | $73.78 | $1.72 |
| P/E Ratio | ★ N/A | $99.82 |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $38.57 | $29.19 |
| 52 Week High | $84.94 | $51.59 |
Technical Indicators
Market Signals| Indicator | BBIO | MGM |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 70.02 |
| Support Level | $62.37 | $34.59 |
| Resistance Level | $69.85 | N/A |
| Average True Range (ATR) | 2.77 | 1.59 |
| MACD | 0.10 | 0.99 |
| Stochastic Oscillator | 46.43 | 74.93 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About MGM MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 56% of total EBITDAR in 2025. MGM also owns US regional assets, which represented a low 20s share of 2025 EBITDAR (MGM's Macao EBITDAR was 23% of the total in 2025). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a second property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.